Sec Form 4 Filing - GOREVIC JASON N @ Teladoc Health, Inc. - 2024-03-01

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
GOREVIC JASON N
2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
CHIEF EXECUTIVE OFFICER
(Last) (First) (Middle)
C/O TELADOC HEALTH, INC.,, 2 MANHATTANVILLE ROAD, SUITE 203
3. Date of Earliest Transaction (MM/DD/YY)
03/01/2024
(Street)
PURCHASE, NY10577
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/01/2024 M 21,130 A 622,864 D
Common Stock 03/01/2024 M 2,915 A 625,779 D
Common Stock 03/01/2024 M 5,782 A 631,561 D
Common Stock 03/01/2024 M 5,615 A 637,176 D
Common Stock 03/01/2024 M 62,004 A 699,180 D
Common Stock 03/01/2024 M 7,648 A 706,828 D
Common Stock 03/04/2024 S 53,755 ( 3 ) D $ 14.516 653,073 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Stock Units ( 4 ) 03/01/2024 A 63,393 ( 5 ) ( 6 ) ( 6 ) Common Stock 63,393 $ 0 63,393 D
Performance Stock Units ( 1 ) 03/01/2024 M 21,130 ( 7 ) ( 7 ) Common Stock 21,130 $ 0 42,263 D
Performance Stock Units ( 1 ) 03/01/2024 M 2,915 ( 8 ) ( 8 ) Common Stock 2,915 $ 0 0 D
Performance Stock Units ( 1 ) 03/01/2024 M 5,782 ( 9 ) ( 9 ) Common Stock 5,782 $ 0 0 D
Restricted Stock Units ( 2 ) 03/01/2024 M 5,615 ( 10 ) ( 10 ) Common Stock 5,615 $ 0 22,460 D
Restricted Stock Units ( 2 ) 03/01/2024 M 62,004 ( 11 ) ( 11 ) Common Stock 62,004 $ 0 124,008 D
Restricted Stock Units ( 2 ) 03/01/2024 M 7,648 ( 12 ) ( 12 ) Common Stock 7,648 $ 0 0 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
GOREVIC JASON N
C/O TELADOC HEALTH, INC.,
2 MANHATTANVILLE ROAD, SUITE 203
PURCHASE, NY10577
X CHIEF EXECUTIVE OFFICER
Signatures
/s/ Adam C. Vandervoort, Attorney-in-Fact 03/05/2024
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
( 2 )Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
( 3 )Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
( 4 )Each performance stock unit represents a contingent right to receive one share of TDOC common stock.
( 5 )Performance award amount determined based on metrics in respect of the issuer's 2023 financial results.
( 6 )The performance stock units vest as to one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
( 7 )On March 1, 2024, the reporting person earned 63,393 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
( 8 )On March 2, 2023, the reporting person earned 5,828 performance stock units, vesting in two substantially equal annual installments beginning on March 2, 2023.
( 9 )On March 2, 2022, the reporting person earned 17,346 performance stock units, vesting in three substantially equal annual installments beginning on March 2, 2022.
( 10 )On March 1, 2022, the reporting person was granted 67,376 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
( 11 )On March 3, 2023, the reporting person was granted 186,012 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
( 12 )On March 2, 2021, the reporting person was granted 22,944 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.